Transfusion and Apheresis Science
Convalescent plasma therapy in patients with COVID-19
The data of severe or critically ill COVID-19 patients who received anti-SARS-CoV-2 antibody-containing
CP along with the antiviral treatment (n = 888) and an age-gender, comorbidity, and other COVID-19 treatments matched severe or critically ill COVID-19 patients at 1:1 ratio (n = 888) were analyzed retrospectively.
Duration in the intensive care unit (ICU), the rate of mechanical ventilation (MV) support and vasopressor support were lower in CP group compared with the control group (p = 0.001, p = 0.02, p = 0.001, respectively). The case fatality rate (CFR) was 24.7 % in the CP group, and it was 27.7 % in the control group. Administration of CP 20 days after the COVID-19 diagnosis or COVID-19 related symptoms were associated with a higher rate of MV support compared with the first 3 interval groups (≤5 days, 6− 10 days, 11− 15 days) (p=0.001).
SARS-CoV-2 Convalescent plasma COVID-19